AbbVie’s psoriasis drug risankizumab has posted strong results in its latest phase 3 trial, as the company prepares to file the drug with global regulators. An interleukin-23 inhibitor ...

Higher concentrations of anti-TNF agents at the end of the induction ... In June, the FDA approved risankizumab (Skyrizi) for moderately to severely active ulcerative colitis based on data from ...

Skyrizi (risankizumab) is the first IL-23-selective ... integrin inhibitors – as well as older branded and biosimilar TNF inhibitors including AbbVie's own blockbuster Humira (adalimumab).

In pregnancy, any anti-TNF alpha, vedolizumab, ustekinumab and risankizumab is safe to use in pregnancy and lactation. We want to avoid the use of S1P inhibitors as well as JAK inhibitors.

TNF alphas are the oldest biologics available ... as well as ulcerative colitis. Risankizumab (Skyrizi, AbbVie) is a newer therapy approved in 2022. It binds to the P-19 subunit of IL-23 with ...